Ann: Uscom NWR Virtual Investor Conference - Company Update, page-45

Be interesting to know if enquiries or sales have increased for the 1a device in recent months in Australia and overseas due to the delta virus affecting far more children globally leading sadly to more needing hospital monitoring.
The 1a has had many positive medical reviews for its major benefits in pediatric care so the sales and distribution teams are hopefully in contact with the people whom are making the medical purchase decisions across their networks for those needing increased care.
i note they have just added a testimonial of the 1a device on their LinkedIn site stating it reduced mortality by 90% however I am unsure if it’s a new testimonial or a re hash post of an old one.
hopefully they have had increased enquiries in the post covid spirosonic lung device also.